DE2527291C2 - - Google Patents

Info

Publication number
DE2527291C2
DE2527291C2 DE2527291A DE2527291A DE2527291C2 DE 2527291 C2 DE2527291 C2 DE 2527291C2 DE 2527291 A DE2527291 A DE 2527291A DE 2527291 A DE2527291 A DE 2527291A DE 2527291 C2 DE2527291 C2 DE 2527291C2
Authority
DE
Germany
Prior art keywords
compound
methyl
salts
dioxo
cephem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2527291A
Other languages
German (de)
English (en)
Other versions
DE2527291A1 (de
Inventor
Marc Dr. Montavon
Roland Dr. Basel Ch Reiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F HOFFMANN-LA ROCHE and Co AG BASEL CH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F HOFFMANN-LA ROCHE and Co AG BASEL CH filed Critical F HOFFMANN-LA ROCHE and Co AG BASEL CH
Publication of DE2527291A1 publication Critical patent/DE2527291A1/de
Application granted granted Critical
Publication of DE2527291C2 publication Critical patent/DE2527291C2/de
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/36Methylene radicals, substituted by sulfur atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19752527291 1974-06-21 1975-06-19 Acylderivate Granted DE2527291A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH853774A CH609989A5 (en) 1974-06-21 1974-06-21 Process for the preparation of acyl derivatives

Publications (2)

Publication Number Publication Date
DE2527291A1 DE2527291A1 (de) 1976-01-08
DE2527291C2 true DE2527291C2 (US20010021848A1-20010913-M00008.png) 1988-01-14

Family

ID=4341690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19752527291 Granted DE2527291A1 (de) 1974-06-21 1975-06-19 Acylderivate

Country Status (25)

Country Link
JP (1) JPS625917B2 (US20010021848A1-20010913-M00008.png)
AT (1) AT337897B (US20010021848A1-20010913-M00008.png)
AU (1) AU498387B2 (US20010021848A1-20010913-M00008.png)
BE (1) BE830455A (US20010021848A1-20010913-M00008.png)
BR (1) BR7503782A (US20010021848A1-20010913-M00008.png)
CA (1) CA1111021A (US20010021848A1-20010913-M00008.png)
CH (1) CH609989A5 (US20010021848A1-20010913-M00008.png)
CU (1) CU34293A (US20010021848A1-20010913-M00008.png)
DD (1) DD121113A5 (US20010021848A1-20010913-M00008.png)
DE (1) DE2527291A1 (US20010021848A1-20010913-M00008.png)
DK (2) DK153155C (US20010021848A1-20010913-M00008.png)
FI (1) FI751815A (US20010021848A1-20010913-M00008.png)
FR (1) FR2275215A1 (US20010021848A1-20010913-M00008.png)
GB (1) GB1471804A (US20010021848A1-20010913-M00008.png)
HU (1) HU170576B (US20010021848A1-20010913-M00008.png)
IE (1) IE41888B1 (US20010021848A1-20010913-M00008.png)
IL (1) IL47299A (US20010021848A1-20010913-M00008.png)
LU (1) LU72771A1 (US20010021848A1-20010913-M00008.png)
NL (1) NL180665C (US20010021848A1-20010913-M00008.png)
NO (1) NO752202L (US20010021848A1-20010913-M00008.png)
NZ (1) NZ177508A (US20010021848A1-20010913-M00008.png)
PH (1) PH13030A (US20010021848A1-20010913-M00008.png)
SE (1) SE431755B (US20010021848A1-20010913-M00008.png)
SU (2) SU635873A3 (US20010021848A1-20010913-M00008.png)
ZA (1) ZA753086B (US20010021848A1-20010913-M00008.png)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7805715A (nl) * 1977-06-03 1978-12-05 Hoffmann La Roche Werkwijze voor het bereiden van acylderivaten.
JPS5419990A (en) * 1977-07-14 1979-02-15 Shionogi & Co Ltd Dihydrotriazinylthioxacephalosporin
MC1259A1 (fr) * 1978-05-30 1980-01-14 Hoffmann La Roche Derives acyles
FR2474030A1 (fr) * 1980-01-17 1981-07-24 Rhone Poulenc Ind Nouvelles dioxotriazines et leur preparation
FR2494278A1 (fr) * 1980-11-20 1982-05-21 Rhone Poulenc Ind Nouveaux derives de la cephalosporine, leurs preparations et les medicaments qui les contiennent
WO2002086143A2 (en) * 2001-04-19 2002-10-31 Bioferma Murcia, S.A. Enzymatic process for preparing cephalosporin derivatives
DK2250156T3 (en) 2008-03-05 2015-08-03 Merck Patent Gmbh Pyrazinonderivater as insulinsekretionsstimulatorer, methods of procurement of them and use thereof for the treatment of diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868369A (en) * 1972-11-14 1975-02-25 Smithkline Corp 3-heterocyclicthiomethylcephalosporins

Also Published As

Publication number Publication date
IE41888L (en) 1975-12-21
SU589921A3 (ru) 1978-01-25
HU170576B (US20010021848A1-20010913-M00008.png) 1977-07-28
DK155329B (da) 1989-03-28
NL7507390A (nl) 1975-12-23
NL180665C (nl) 1987-04-01
CU34293A (es) 1979-01-16
FR2275215A1 (fr) 1976-01-16
JPS5113793A (US20010021848A1-20010913-M00008.png) 1976-02-03
NL180665B (nl) 1986-11-03
SE431755B (sv) 1984-02-27
PH13030A (en) 1979-11-15
DK155329C (da) 1989-08-07
DK271975A (da) 1975-12-22
GB1471804A (en) 1977-04-27
BE830455A (fr) 1975-12-22
AU498387B2 (en) 1979-03-08
BR7503782A (pt) 1976-07-06
IE41888B1 (en) 1980-04-23
AT337897B (de) 1977-07-25
DD121113A5 (US20010021848A1-20010913-M00008.png) 1976-07-12
NZ177508A (en) 1978-04-03
ATA476975A (de) 1976-11-15
SU635873A3 (ru) 1978-11-30
FI751815A (US20010021848A1-20010913-M00008.png) 1975-12-22
CA1111021A (en) 1981-10-20
IL47299A0 (en) 1976-10-31
IL47299A (en) 1979-01-31
FR2275215B1 (US20010021848A1-20010913-M00008.png) 1980-05-16
LU72771A1 (US20010021848A1-20010913-M00008.png) 1977-03-04
SE7506908L (sv) 1975-12-22
DK453687A (da) 1987-08-28
DK453687D0 (da) 1987-08-28
DK153155C (da) 1988-10-31
AU8191275A (en) 1976-12-09
DE2527291A1 (de) 1976-01-08
ZA753086B (en) 1976-04-28
NO752202L (US20010021848A1-20010913-M00008.png) 1975-12-23
DK153155B (da) 1988-06-20
JPS625917B2 (US20010021848A1-20010913-M00008.png) 1987-02-07
CH609989A5 (en) 1979-03-30

Similar Documents

Publication Publication Date Title
CH629499A5 (de) Verfahren zur herstellung neuer cephalosporinderivate.
DE3311300C2 (US20010021848A1-20010913-M00008.png)
DE2954159C2 (de) acetamido] cephalosporansäure-Derivate und deren Herstellung
CH639666A5 (de) Cephalosporansaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung.
CH641468A5 (de) Cephemderivate.
DE2736471C2 (US20010021848A1-20010913-M00008.png)
CH617202A5 (US20010021848A1-20010913-M00008.png)
CH622262A5 (US20010021848A1-20010913-M00008.png)
DE3233377A1 (de) Cephalosporinisochinoliniumbetaine und sie enthaltende pharmazeutische mittel
DE3307550C2 (US20010021848A1-20010913-M00008.png)
DE2527291C2 (US20010021848A1-20010913-M00008.png)
DE3005888A1 (de) 3-phosphonocephalosporansaeure- derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische mittel
EP0280157B1 (de) Kristallisierte Cephem-Säureadditionssalze und Verfahren zu ihrer Herstellung
DE3887443T2 (de) Azetidinylchinoloncarbonsäure und Ester.
EP0049855B1 (de) Neue Cephalosporinderivate, Verfahren zu ihrer Herstellung und Zwischenprodukte dafür sowie entsprechende pharmazeutische Präparate
CH636879A5 (de) Verfahren zur herstellung 7-substituierter aminoacetamido-oxadethia-cephalosporine.
EP0000005B1 (de) Neue Cephalosporinderivate, Verfahren zu ihrer Herstellung und pharmazeutische Präparate
EP0029966A2 (de) Cephalosporinderivate, und deren Herstellung sowie entsprechende pharmazeutische Präparate
DE2700271A1 (de) Thienopyridinderivate
DE69816057T2 (de) Antibakterielle substituierte 7-acylamino-3-(methylhydrazono)methyl-cephalosporine und zwischenprodukte
EP0075104A2 (de) Cephalosporinderivate, Verfahren zu deren Herstellung und Zwischenprodukte dafür sowie entsprechende pharmazeutische Präparate
DE2655717A1 (de) Thiadiazolylderivate von 7-acylamido-3-cephem-4-carbonsaeure, verfahren zu deren herstellung und dieselben enthaltende pharmazeutische und veterinaermedizinische mittel
DE2559932C2 (de) Cephalosporine, Verfahren zur Herstellung derselben und Mittel mit einem Gehalt derselben
EP0036652A2 (de) Cephalosporinderivate, entsprechende Präparate, die Verwendung dieser Produkte bei der Behandlung von Krankheiten, die Herstellung der Wirkstoffe sowie dabei anfallende Zwischenprodukte
DE2852745A1 (de) Neue penicillin- und cephalosporinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
Q176 The application caused the suspense of an application

Ref document number: 2534071

Country of ref document: DE

D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: F. HOFFMANN-LA ROCHE AG, BASEL, CH

8328 Change in the person/name/address of the agent

Free format text: LEDERER, F., DIPL.-CHEM. DR., 8000 MUENCHEN RIEDERER FRHR. VON PAAR ZU SCHOENAU, A., DIPL.-ING., PAT.-ANWAELTE, 8300 LANDSHUT